2019
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety 2019, 42: 751-768. PMID: 30739254, PMCID: PMC6520311, DOI: 10.1007/s40264-019-00797-3.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsPsoriatic arthritisRegistrational trialsCrohn's diseaseMajor adverse cardiovascular eventsUstekinumab-treated patientsAdverse cardiovascular eventsSevere plaque psoriasisConsistent safety profileSevere Crohn's diseaseActive psoriatic arthritisClinical development programUstekinumab doseCardiovascular eventsPlaque psoriasisBiologic agentsPsoriatic patientsInduction doseSafety profileIncidence rateSafety dataPatientsDiseaseSafety eventsWeeks
2013
Community differentiation of the cutaneous microbiota in psoriasis
Alekseyenko A, Perez-Perez G, De Souza A, Strober B, Gao Z, Bihan M, Li K, Methé B, Blaser M. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013, 1: 31. PMID: 24451201, PMCID: PMC4177411, DOI: 10.1186/2049-2618-1-31.Peer-Reviewed Original ResearchCutaneous microbiotaLesion specimensCommon chronic inflammatory diseaseSkin typeChronic inflammatory diseasePsoriasis patientsPsoriatic patientsContralateral skinDifferential microbiotaInflammatory diseasesSkin colonizationHealthy controlsPsoriatic lesionsLesion siteDiagnostic significanceLesion samplesClinical diagnosisPsoriasis samplesPsoriasisSystemic levelsUseful predictorConclusionsOur resultsMicrobiotaPatientsLesions
2010
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
Leonardi C, Strober B, Gottlieb A, Elewski B, Ortonne J, van de Kerkhof P, Chiou C, Dunn M, Jahreis A. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. Journal Of Drugs In Dermatology 2010, 9: 928-37. PMID: 20684143.Peer-Reviewed Original ResearchConceptsLong-term safetyExtension studyOpen-label etanercept treatmentPrevious phase 3 studyOpen-label extension studyEfficacy of etanerceptOpen-label studySevere plaque psoriasisPhase 3 studySymptoms of psoriasisEligible patientsEtanercept treatmentInterrupted therapySubcutaneous etanerceptEtanercept therapyPlaque psoriasisAdverse eventsPsoriatic patientsEtanerceptPatientsSkin diseasesPsoriasisWeeksYears of experiencePredetermined criteriaThe treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
Levine D, Strober B. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Seminars In Cutaneous Medicine And Surgery 2010, 29: 28-34. PMID: 20430305, DOI: 10.1016/j.sder.2010.02.003.Peer-Reviewed Original ResearchConceptsSevere psoriasisUS FoodDrug AdministrationTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsInterleukin-12/23 inhibitorsShort-term safetyT-cell modulatorDevelopment of biologicsBiologic therapyPsoriasis patientsPsoriatic patientsClinical trialsTherapeutic monitoringSpecific patientPatientsBiologicsMedicationsPsoriasisLong-term dataAdministrationTreatmentCurrent bodyInhibitorsEvidence
2008
Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions
Gao Z, Tseng C, Strober B, Pei Z, Blaser M. Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions. PLOS ONE 2008, 3: e2719. PMID: 18648509, PMCID: PMC2447873, DOI: 10.1371/journal.pone.0002719.Peer-Reviewed Original ResearchConceptsPsoriatic lesionsHealthy personsIdiopathic inflammatory disorderNormal skin samplesBroad-range PCRPsoriatic patientsInflammatory disordersUninvolved skinPsoriatic skinCutaneous samplesNormal skinPatientsLesion samplesNormal personsSubstantial alterationsLesionsPropionibacterium speciesSkin samplesPsoriasisSkinSpecies-level operational taxonomic unitsRDNA PCRAlterationsExtracted DNARange PCR
2004
Efficacy of etanercept in psoriatic patients previously treated with systemic therapy or phototherapy
Strober B, Yamauchi P, Korman N, Stevens S. Efficacy of etanercept in psoriatic patients previously treated with systemic therapy or phototherapy. Journal Of The American Academy Of Dermatology 2004, 50: p147. DOI: 10.1016/j.jaad.2003.10.512.Peer-Reviewed Original Research